Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

Gregory Cheng, Mansoor N Saleh, Claus Marcher, Sandra Vasey, Bhabita Mayer, Manuel Aivado, Michael Arning, Nicole L Stone, James B Bussel

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune thrombocytopenia during a 6-month period.
OriginalsprogEngelsk
TidsskriftLancet
Vol/bind377
Udgave nummer9763
Sider (fra-til)393-402
ISSN0140-6736
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study'. Sammen danner de et unikt fingeraftryk.

Citationsformater